

## Proof of concept study completed into the safety and efficacy of new medicinal cannabis product

- Study to assess the safety and efficacy of cannabigerol (CBG) dominant cannabis extract completed with promising results
- Trial forms the basis for the launch of a new medicinal cannabis product under Bod's existing brand as MediCabilis™ CBG 50 – product to be marketed and sold in June 2022 through prescription markets
- CBG is a non-intoxicating cannabinoid which holds strong potential for broad therapeutic use
- Bod's study was undertaken over three months to investigate the effect of CBG on symptoms associated with fibromyalgia, inflammatory bowel disease and anxiety
- 74% of trial participants reported a noticeable improvement in their conditions within two to four weeks of using MediCabilis™ CBG 50
- Data from the study to be used in Bod's ongoing doctor and approved prescriber outreach with healthcare professionals in Australia and the UK
- Bod to become the first company to introduce a pharmaceutical grade CBG product in the Australian and UK prescription market – provides another channel to increase market share and sales

**Sydney, Australia – 25 May 2022:** Cannabis focused drug development and product innovation company Bod Australia Limited ("Bod" or "the Company") (ASX: BOD) is pleased to advise that it has completed a proof of concept study into the safety and efficacy of a cannabigerol (CBG) dominant cannabis extract which has shown very promising results. The study will form the basis for the launch of a new medicinal cannabis product that will be sold under Bod's existing medicinal cannabis brand as MediCabilis™ CBG 50, expected to launch in June 2022.

CBG is a non-intoxicating cannabinoid compound, found in the cannabis plant. It holds strong therapeutic potential across a range of applications. Preliminary research has indicated that CBG has unique pharmacological actions and has the potential to address alternative therapeutic areas to THC and CBD. The extract has been shown to be beneficial in the treatment of fibromyalgia, inflammatory bowel disease and irritable bowel syndrome (IBS) amongst others. Treatment of these conditions commonly includes a mix medication, surgery and self-care strategies, with no single treatment procedure working on all symptoms<sup>1</sup>.

Bod's proof of concept study was conducted over a three month period to assess the safety and efficacy of MediCabilis™ CBG 50 in patients suffering from symptoms associated with fibromyalgia, inflammatory bowel disease and anxiety. During the trial, participants were administered 50mg/ml of the product orally, twice daily and asked to rate the improvement in symptoms on a scale of one to ten, with one being nothing to ten being the best improvement.

A comprehensive review of the data highlighted that 74% of trial participants reported a noticeable improvement in their conditions within two to four weeks of using MediCabilis™ CBG 50 twice a day. When participants were asked to rate the improvement on a scale of one to ten, 64% reported a rating above six.

The detailed trial data will be shared with doctors and approved prescribers in both Australia and the UK to assist in the ongoing educational initiatives undertaken by the Company and to support the launch of MediCabilis™ CBG 50.

The Company expects to launch MediCabilis™ CBG 50 in June 2022 via prescription channels. This will complement and expand Bod's existing medicinal cannabis product range, which is currently being used to alleviate a range of conditions including chronic pain, anxiety and insomnia amongst others. Bod will also become the first company to launch a pharmaceutical grade CBG product in the Australian and UK prescription market, providing another channel to grow medicinal cannabis sales.

### CONTACT

T +61 2 9199 5018 E [info@bodaustralia.com](mailto:info@bodaustralia.com) [bodaustralia.com](http://bodaustralia.com)

For personal use only

**CEO Ms Jo Patterson said:** *“The completion of this initiative has highlighted that MediCabilis™ CBG 50 is both safe and effective for use across a range of new symptoms that our product has not been previously prescribed for. The study will also allow Bod to explore the possibility of using its extract as an alternative treatment or all encompassing route for conditions that require a mix of surgery, medication and other routines. We look forward to leveraging the data from the study to continue our educational outreach with doctors and approved prescribers in Australia. These discussions with healthcare professionals will drive additional sales in the UK and Australia.*

*“The Company continues to make very pleasing progress on its R&D initiatives. We are very confident that outcomes from our clinical trial pipeline trials will create meaningful opportunities in drug and product development for our own brands and potential licencing agreements with large pharmaceutical companies and other enterprises.”*

**This announcement has been approved by the Board of Bod Australia Limited.**

**-ENDS-**

**About Bod Australia:**

Bod Australia Limited (ASX:BOD) Bod is a cannabis focused drug development and product innovation company.

Bod is focused on progressing R&D and a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for the consumer and medical markets.

The company has a number of existing partnerships with large corporate groups and collaborations with leading research partners to advance the use of CBD.

**For more information please contact:**

Jo Patterson  
Chief Executive Officer  
Info@bodaustralia.com  
+61 2 9199 5018

Henry Jordan  
Six Degrees Investor Relations  
Henry.jordan@sdir.com.au  
+61 431 271 538

---

<sup>i</sup> <https://www.mayoclinic.org/diseases-conditions/fibromyalgia/diagnosis-treatment/drc-20354785> & <https://www.mayoclinic.org/diseases-conditions/inflammatory-bowel-disease/diagnosis-treatment/drc-20353320>